GLP-1 and Pregnancy: Safety, Washout Period & Planning

Introduction

Pregnant patients shouldn’t take semaglutide or tirzepatide. That’s the consistent guidance from the FDA, from the manufacturers, and from major obstetric organizations. But what that means in practice (when to stop, what to do if you conceive on the drug, how to plan a future pregnancy) is more nuanced than the simple contraindication suggests.

This article covers the regulatory guidance, the animal data behind it, what the limited human exposure data shows, and the practical decisions women on GLP-1 drugs face around pregnancy.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

Why Are GLP-1 Drugs Contraindicated in Pregnancy?

The contraindication comes from animal data, not human studies. Reproductive toxicity studies in rats and rabbits showed dose-related embryofetal growth reductions, skeletal abnormalities, and visceral malformations at exposures similar to therapeutic human doses. These findings led to the FDA pregnancy contraindication for both Wegovy® and Zepbound®.

Quick Answer: Both semaglutide and tirzepatide are pregnancy contraindicated based on animal teratogenicity, with FDA labels recommending discontinuation at least 2 months before planned conception

The mechanism of teratogenicity isn’t fully understood. GLP-1 receptors are expressed in developing embryonic tissues. Both reduced maternal nutrition (from the drug’s appetite-suppressing effects) and direct GLP-1 receptor activation in the fetus may contribute.

The animal data is sufficient for a precautionary contraindication. The actual human risk may be smaller, larger, or different, but ethics rule out controlled trials in pregnant women.

What Does the Human Exposure Data Show?

Reassuring but limited. The largest published analysis is the 2024 Cesta and colleagues paper in JAMA Internal Medicine, which used insurance claims data to identify over 50,000 pregnancies exposed to GLP-1 receptor agonists in the first trimester. Major congenital malformation rates were similar to background population rates, with no clear excess in cardiac defects, neural tube defects, or other common categories.

The study had limitations. Most exposures were to older GLP-1 drugs like liraglutide and exenatide rather than to semaglutide or tirzepatide. The follow-up was relatively short. Outcomes other than major malformations weren’t well captured.

A 2023 paper from the same database analyzed liraglutide exposure specifically and found similar results. No teratogenic signal so far, but the data is still maturing.

What Should I Do If I Conceive While on GLP-1?

Stop the drug immediately. Take a pregnancy test if you suspect pregnancy. Call your prescriber and your OB.

The standard recommendation is to continue the pregnancy with usual prenatal care. The exposure has already occurred. Termination is not medically indicated based on the current data.

Early prenatal care includes the usual screening (first trimester ultrasound, nuchal translucency, maternal serum markers) and standard genetic screening. Some OBs offer additional anatomy ultrasound at 18-20 weeks given the medication exposure.

Document the timing of exposure carefully. The first trimester is the most sensitive window for major malformations. Second and third trimester exposure may have different risks, including effects on fetal growth and amniotic fluid volume.

When Should I Stop the Drug If Planning Pregnancy?

The FDA-recommended minimum is 2 months before active conception attempts. This is based on the elimination half-life of semaglutide (about 1 week) and tirzepatide (about 5 days), with several half-lives plus a safety buffer.

Many clinicians prefer 2-3 months. Some recommend longer if there’s flexibility in timing. Stopping 6 months ahead is overkill from a pharmacological standpoint, but some patients prefer the extra buffer.

The drug is essentially completely cleared from the body by 2 months. Detectable levels in blood and tissues are very low.

Will I Regain Weight During the Washout Period?

Yes, usually. The STEP 4 trial by Rubino et al. 2021 JAMA showed about 6.9% of weight regained over the first 6 months after stopping semaglutide. Most of this regain happens in the first 3-4 months.

For pregnancy planning, this is a real consideration. Some women have a window after the medical washout where they can still attempt conception at an improved weight. Others find weight returning quickly and may want to start attempts soon after the 2-month minimum.

There’s no medical reason to delay conception attempts beyond the washout period. Whether to extend the wait to capture more weight loss before pregnancy is a personal calculation.

How Does Pregnancy Affect Existing Weight Management?

Pregnancy is generally not a time to actively pursue weight loss. The American College of Obstetricians and Gynecologists recommends weight gain during pregnancy based on starting BMI, with overweight women advised to gain 15-25 pounds and obese women 11-20 pounds.

That said, some pregnant women with significant obesity may benefit from limited gain or even modest loss in the first trimester under close supervision. This is done through diet rather than medication. GLP-1 drugs aren’t an option during pregnancy.

Gestational diabetes affects 6-9% of pregnancies in the US, and is more common in women with prior obesity. Treatment during pregnancy uses insulin or metformin, both of which have extensive safety data in pregnancy.

What About Postpartum Use of GLP-1?

GLP-1 drugs are not recommended during breastfeeding. Whether the drug passes into breast milk in clinically significant quantities is unclear. Both Novo Nordisk and Eli Lilly recommend against use during breastfeeding based on the precautionary principle.

After weaning, GLP-1 treatment can resume normally. Many women find postpartum weight loss difficult, especially after multiple pregnancies and during sleep-deprived early infancy. GLP-1 drugs are a reasonable option once breastfeeding has ended.

See our breastfeeding article for more detail.

What About Pregnancies in Women with Diabetes on GLP-1?

The same general guidance applies, with additional considerations. Women with diabetes who become pregnant need tight glucose control, typically with insulin rather than oral or GLP-1 medications. The transition should happen before conception when possible.

The SUSTAIN trials by Sorli et al. and others were not designed to include pregnancy, and the diabetes labels for semaglutide also include pregnancy contraindications. Pre-pregnancy planning with an endocrinologist and an OB is the standard recommendation for women with diabetes on GLP-1 drugs.

Key Takeaway: Inadvertent early-pregnancy exposure is increasingly common given the population now on GLP-1 drugs and unexpected fertility recovery

What Does the Assessment Quiz Ask About Pregnancy Plans?

The TrimRx intake covers current pregnancy, breastfeeding status, contraception, and pregnancy plans. Women who are currently pregnant or planning to conceive in the next 3 months are generally not appropriate candidates for starting GLP-1 treatment.

If you start the medication and then decide to pursue pregnancy, contact the medical team. They can guide the transition off the drug, recommend washout timing, and refer you back to your OB or primary care for ongoing weight management during the wait.

What About Pregnancy Outcomes in Mothers WHO Lost Significant Weight Before Conception?

The available evidence suggests pre-pregnancy weight loss generally improves pregnancy outcomes. Lower rates of gestational diabetes, preeclampsia, cesarean delivery, and macrosomia have been documented in women who lost significant weight before conception, regardless of the method.

A 2023 cohort study in Obstetrics & Gynecology compared pregnancy outcomes in women with prior bariatric surgery versus matched obese controls and found substantially lower rates of complications. Similar patterns probably apply to GLP-1-induced weight loss before pregnancy, though specific prospective data is still maturing.

What this means practically: planning a pregnancy from a lower starting weight after GLP-1 treatment is generally favorable, as long as the 2-month washout is observed.

Should I Worry About the Drug Being Present in Early Embryonic Development?

The first 8 weeks of pregnancy include the embryonic period where major organ systems form. This is when teratogen sensitivity is highest. If pregnancy occurs within the recommended 2-month washout window after stopping GLP-1, very little drug should still be present, since the drug is effectively cleared by 4-5 elimination half-lives.

The 2-month washout is designed specifically to ensure essentially complete drug clearance before any conception attempt. Inadvertent exposure during the first month after stopping the drug has not been associated with clear teratogenic patterns in the available data, but the formal recommendation is to wait the full 2 months.

What Is the Medical Follow-up After a GLP-1-exposed Pregnancy?

Standard prenatal care plus enhanced monitoring. First-trimester screening including nuchal translucency, maternal serum markers, and ultrasound at 12 weeks. Anatomy scan at 18-20 weeks, sometimes with additional imaging if concerns arise. Glucose tolerance testing at the usual 24-28 week window.

After delivery, infant evaluation includes standard newborn screening plus any specific assessments recommended by the pediatrician based on the exposure timing.

Most pregnancies with first-trimester GLP-1 exposure proceed normally based on the available data, but enhanced surveillance is reasonable.

What Does the International Guidance Look Like?

Most regulatory agencies align with the FDA position. The European Medicines Agency, Health Canada, the UK MHRA, and the Australian TGA all classify GLP-1 receptor agonists as contraindicated in pregnancy with similar washout recommendations.

The American College of Obstetricians and Gynecologists hasn’t issued formal stand-alone guidance on GLP-1 in pregnancy beyond endorsing the manufacturer recommendations. Maternal-fetal medicine specialists generally follow the 2-month washout and discontinuation at pregnancy diagnosis.

The accumulating real-world data may shift guidance over time, particularly if larger pregnancy registries confirm or refute the rodent teratogenicity signal in humans. For now, the precautionary contraindication remains the standard of care.

Final Practical Takeaway

Stop GLP-1 at least 2 months before planned pregnancy. Use effective non-oral contraception during treatment. Stop immediately if you discover an unplanned pregnancy and continue prenatal care normally. The available human data on inadvertent exposure is reassuring but limited. Coordinate care between your prescriber, your OB, and any specialists involved in your pregnancy planning. The TrimRx assessment quiz screens for pregnancy plans during intake.

FAQ

How Early in Pregnancy Should I Stop the Drug?

The moment you know you’re pregnant. There’s no benefit to continuing the drug into pregnancy and there are theoretical risks.

Does the 2-month Washout Apply to Every Dose Level?

Yes. The recommendation is for any dose level. Higher doses produce more sustained exposure, but the elimination half-life is the same regardless of dose.

Can I Take Folate or Other Prenatal Supplements While on GLP-1?

Yes, and you should if you’re considering pregnancy. Standard prenatal vitamins with folate (400-800 mcg daily) should be started at least 1 month before conception attempts, regardless of GLP-1 use.

What If I’m Not Sure When I Conceived Relative to My Last Dose?

Document what you know, share with your OB, and continue prenatal care. The available human data is reassuring across various exposure timings. The risk of inadvertent exposure is small.

Does Breastfeeding Affect When I Can Restart GLP-1?

Yes, current guidance is to wait until breastfeeding has ended before resuming GLP-1 treatment. There’s no fixed waiting period after weaning, but most clinicians wait at least a few days for the drug to begin establishing levels before considering it safe to resume any breast milk feeding.

Is There a Registry for Pregnancy Outcomes on GLP-1?

Yes, both Novo Nordisk and Eli Lilly maintain pregnancy registries for their GLP-1 products. If you’ve had pregnancy exposure, your OB can register your case to contribute to the safety data.

What’s the Difference Between Contraindicated and Prohibited?

Contraindicated means the drug shouldn’t be used because the risks outweigh the benefits. Prohibited would be a legal restriction. The pregnancy contraindication is medical guidance, not a legal prohibition, and inadvertent exposure does not violate any law or warrant punitive response from a healthcare team.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.